Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LC-MS-based urine metabolomics analyses for early diagnosis of medulloblastoma

ABSTRACT: we applied liquid chromatography - mass spectrometry (LC-MS) based metabolomics to analyze a cohort including 420 urine samples

ORGANISM(S): Homo Sapiens

SUBMITTER: Wei Sun

PROVIDER: PXD016453 | iProX | Wed Nov 27 00:00:00 GMT 2019

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Urine Metabolomics and Colorectal Cancer Screening

Project description:This is a prospective, multi-centered study to assess whether urine metabolomics can play a role in the screening of colorectal cancer (CRC). Urine samples will be collected from 1000 patients going through an established CRC screening program, and from a further 500 patients who already have a diagnosis of CRC. Using nuclear magnetic resonance (NMR) spectroscopy, the 1H NMR spectrum of urine samples will be analyzed for specific metabolites, and establish the metabolomic signature of colorectal cancer. The results from metabolomic urinalysis of this screening cohort will be compared with results from colonoscopy, histological descriptions, fecal occult blood testing (FOBT), and fecal immune testing (FIT) to assess the accuracy of urine metabolomics in identifying patients with polyps and malignancies. The urine metabolomic results from the colorectal cancer group will be correlated with operative, histological and clinical staging to define the role of urine metabolomics in assessing colorectal cancer type, location and stage. Additionally approximately 300 urine samples from breast cancer patients and 300 from prostate cancer patients will be collected to validate that the colorectal cancer signature is unique.

| 2116822 | ecrin-mdr-crc

Monitoring advanced adenoma and early colorectal cancer by urine metabolomics

Project description:Interventions: Control Group:none;Advanced Adenoma Group:none;Early Colorectal Cancer Group:none Primary outcome(s): urine metabolomics Study Design: Factorial

| 2702218 | ecrin-mdr-crc

LC-MS-based urine metabolomics analysis of chronic subdural hematoma for biomarker discovery

Project description:A comprehensive liquid chromatography-mass spectrometry (LC-MS) based metabolomics was utilized to find the specific urine metabolites in a cohort to discriminate urine metabolome profiles, including healthy controls and patients with CSDH.

2022-11-21 | PXD038258 |

Characterization of LC-MS based urine metabolomics in healthy children and adults

Project description:In this study, we provided a comprehensive lifespan characterization of urine metabolomics in a cohort of 348 healthy children and 315 adults aged 1 to 70 years using liquid chromatography coupled with high resolution mass spectrometry.

2022-06-06 | PXD034390 |

LC-MS-Based Urine Metabolomics Analysis for the Diagnosis and Monitoring of Medulloblastoma.

Project description:Medulloblastoma (MB) is the most common type of brain cancer in pediatric patients. Body fluid biomarkers will be helpful for clinical diagnosis and treatment. In this study, liquid chromatography-mass spectrometry (LC-MS)-based metabolomics was used to identify specific urine metabolites of MB in a cohort, including 118 healthy controls, 111 MB patients, 31 patients with malignant brain cancer, 51 patients with benign brain disease, 29 MB patients 1 week postsurgery and 80 MB patients 1 month postsurgery. The results showed an apparent separation for MB vs. healthy controls, MB vs. benign brain diseases, and MB vs. other malignant brain tumors, with AUCs values of 0.947/0.906, 0.900/0.873, and 0.842/0.885, respectively, in the discovery/validation group. Among all differentially identified metabolites, 4 metabolites (tetrahydrocortisone, cortolone, urothion and 20-oxo-leukotriene E4) were specific to MB. The analysis of these 4 metabolites in pre- and postoperative MB urine samples showed that their levels returned to a healthy state after the operation (especially after one month), showing the potential specificity of these metabolites for MB. Finally, the combination of two metabolites, tetrahydrocortisone and cortolone, showed diagnostic accuracy for distinguishing MB from non-MB, with an AUC value of 0.851. Our data showed that urine metabolomics might be used for MB diagnosis and monitoring.

| S-EPMC9353006 | biostudies-literature

UPLC-MS based urine metabolomics for bladder cancer diagnosis and grading

Project description:In our study, we collected urine samples from 246 cases, including 131 BC patients, 27 benign bladder disease patients, and 88 healthy adults as the control group. Ultra-performance liquid chromatography coupled to mass spectrometry (UPLC-MS) was applied for urine metabolomics analysis to distinguish the BC group from the healthy controls and the benign group, and the low-grade BC group from the high-grade BC group.

2024-11-27 | PXD058310 |

Non-invasive diagnosis of urothelial cancer in urine using DNA hypermethylation signatures

Project description:Methylation status of free DNA from urine from patients with urothelial tumor and healthy control patients were analysed

2018-09-22 | GSE120288 | GEO

Epigenome and transcriptome profiling of urine progenitor renal cells

Project description:We characterized the transcriptome and methylome of renal progenitor cells in the urine of a cohort of stable kidney transplant recipients to elucidate whether the origin of the donor (living or deceased donor) was associated with a specific molecular reprogramming.

2025-05-08 | GSE235813 | GEO

Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

Project description:Intra-individual stability of the urine miRNA transcriptome was examined by investigating longitudinal changes over time in a cohort of patients with localized prostate cancer. Using training and validation cohorts, urinary miRNA biomarkers are characterized and validated their utility to identify aggressive prostate cancer.

2019-10-24 | GSE104431 | GEO

Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

2019-10-24 | GSE104430 | GEO